Back to top

Image: Bigstock

Myriad Genetics, Inc.

Read MoreHide Full Article

Over the past year, Myriad Genetics has outperformed its industry. The company observed strong growth in GeneSight, EndoPredict and Prolaris testing revenues. Further, management believes that Hereditary cancer pricing has remained stable on a sequential basis for four consecutive quarters. We are upbeat about Myriad Genetics’ expectation to witness a stable pricing trend in the same to continue throughout fiscal 2019. Moreover, on solid performance by new products, Counsyl buyout synergy, success of the Elevate 2020 program along with augmenting reimbursements for the tests, the company seems to be well-positioned to deliver strong financial results in fiscal 2019.  However, the decline in Hereditary cancer testing revenues raises concern. Currency fluctuations and stiff competition are other concerning factors.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Myriad Genetics, Inc. (MYGN) - free report >>

Published in